SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action
The DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index.
Abstract
There is compelling evidence that sodium–glucose cotransporter 2 (SGLT2) inhibitors exert cardioprotective and renoprotective effects that are far greater than expected based on their effects on glycemia or glycosuria. In large-scale randomized controlled trials, SGLT2 inhibitors reduce the risk of hospitalizations for heart failure by ∼30% and often decrease the risk of cardiovascular death (1). This benefit is particularly striking in patients who have the most marked impairment of systolic function prior to treatment. In parallel, SGLT2 inhibitors also reduce the risk of end-stage renal events, including the occurrence of renal death and the need for dialysis or renal transplantation by ∼30% (2). This benefit is seen even when glomerular filtration rates are sufficiently low to abolish the glycosuric effect of these drugs. These cardiorenal benefits cannot be explained by an action of SGLT2 inhibitors to lower blood glucose, since similar effects are not seen with antidiabetes drugs that have greater antihyperglycemic actions. Additionally, they cannot be ascribed to a natriuretic action, since these drugs exert only a modest effect on plasma volume or on circulating natriuretic peptides (3). In 2016, two articles published in Diabetes Care proposed the “thrifty fuel hypothesis” to explain the cardiorenal benefits of SGLT2 inhibitors. Ferrannini et al. (4) and Mudaliar et al. (5) postulated that the action of SGLT2 inhibitors to promote ketogenesis might account for their favorable effects on the heart and kidney because enhanced ketone bodies formation might possibly provide an efficient fuel that could boost the energy state of organs under stress. However, type 2 diabetes represents a state of nutrient overabundance and not energy deprivation, as is evidenced by the enhancement of molecular pathways that promote both energy retention (e.g., through SGLT2 upregulation) and energy storage (6,7). In fact, the stressed heart already preferentially utilizes ketone bodies, …
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, according to Packer M, SGLT2 inhibitors cause transcriptional changes in cells that occur during starvation, which is called “state of fasting mimicry” and include SIRT/AMPK activation and Akt/mTOR suppression (Figure 3).”
From Neuroprotective effect of SGLT2 inhibitors. (2021) · cites this paper as [106]
In the citing paper
“Moreover, taking flozins causes changes similar to an ischemic state, including HIF-2α activation which stimulates erythropoiesis, and patients with higher erythrocyte count benefited most from SGLT2i therapy.”
From Neuroprotective effect of SGLT2 inhibitors. (2021) · cites this paper as [106]
Citations
Cites
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux
Samuel, V. T., & Shulman, G. I. (2016) · Journal of Clinical Investigation · doi:10.1172/jci77812 · Cited by 1,484
Sirt1 Regulates Aging and Resistance to Oxidative Stress in the Heart
Alcendor, R. R., Gao, S., Zhai, P., Zablocki, D., Holle, E., Yu, X., Tian, B., Wagner, T., Vatner, S. F., & Sadoshima, J. (2007) · Circulation Research · doi:10.1161/01.res.0000267723.65696.4a · Cited by 1,147
CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dc16-0330 · Cited by 975
Neuen, B. L., Young, T., Heerspink, H. J. L., Neal, B., Perkovic, V., Billot, L., Mahaffey, K. W., Charytan, D. M., Wheeler, D. C., Arnott, C., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30256-6 · Cited by 893
Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., Schmoor, C., Ohneberg, K., Johansen, O. E., George, J. T., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1096 · Cited by 740 · cited 1×
“Such a relationship may explainwhy, in statisticalmediation analyses, erythrocytosis has been the most powerful predictor of the action of SGLT2 inhibitors to reduce heart failure events in large-scale trials (44,45).”
BackgroundThe Failing Heart Relies on Ketone Bodies as a Fuel
Aubert, G., Martin, O. J., Horton, J. L., Lai, L., Vega, R. B., Leone, T. C., Koves, T., Gardell, S. J., Krüger, M., Hoppel, C. L., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.017355 · Cited by 707
Mudaliar, S., Alloju, S., & Henry, R. R. (2016) · Diabetes Care · doi:10.2337/dc16-0542 · Cited by 571
Zhou, H., Wang, S., Zhu, P., Hu, S., Chen, Y., & Ren, J. (2018) · Redox Biology · doi:10.1016/j.redox.2017.12.019 · Cited by 550
Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program
Rådholm, K., Figtree, G., Perkovic, V., Solomon, S. D., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Barrett, T. D., Shaw, W., Desai, M., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034222 · Cited by 488
Research works printed but not linked: 1
- Balaiya, 2012, Hypoxia initiates sirtuin1-mediated vascular endothelial growth factor activation in choroidal endothelial cells through hypoxia inducible factor-2α, Mol Vis, 18, 114
Cited by
Items 101–200 of 247
Alkabbani, W., Zongo, A., Minhas‐Sandhu, J. K., Eurich, D. T., Shah, B. R., Alsabbagh, M. W., & Gamble, J. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002496 · Cited by 19
SGLT2 Inhibitors May Restore Endothelial Barrier Interrupted by 25-Hydroxycholesterol
Pawlos, A., Broncel, M., Woźniak, E., Markiewicz, Ł., Piastowska‐Ciesielska, A. W., & Gorzelak‐Pabiś, P. (2023) · Molecules · doi:10.3390/molecules28031112 · Cited by 14
“The improvement of the endothelial barrier function caused by flozins may be due to their ability to modulate cellular metabolism, observed even in cells that do not express SGLT2 receptors [13].”
BackgroundFerreira, A., Schönenberger, K. A., Potoczna, N., Vogt, A. P., Gerber, P. A., Zehetner, J., Giachino, D., Nett, P. C., Gawinecka, J., Cossu, L., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0036 · Cited by 16
“While the reduction of glycemic variability and other, glucose-independent, protective effects 39,40 may offer potential benefits to patients with PBH, the exact therapeutic role of SGLT2 inhibitors in this population requires further investigation.”
Surprises in cardiology: efficacy of gliflozines in heart failure even in the absence of diabetes
Bragagni, A., Piani, F., & Borghi, C. (2021) · European Heart Journal Supplements · doi:10.1093/eurheartj/suab094 · Cited by 14
“The real peculiarity of these molecules that differentiates them from the canonical loop diuretics is the ability to stimulate an osmotic diuresis: the glucose not reabsorbed at the level of the proximal convoluted tubule reaches the distal nephron, causing an increase in tubular osmolarity and reducing the osmotic gr…”
BackgroundInfluentialMolecular Aspects of Lifestyle and Environmental Effects in Patients With Diabetes
Nayor, M. G., Shah, S. H., Murthy, V. L., & Shah, R. V. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.02.070 · Cited by 13
Ng, P. Y., Ng, A. K., Ip, A., Wu, M., Guo, R., & Yiu, K. (2023) · Critical Care Medicine · doi:10.1097/ccm.0000000000005869 · Cited by 17
“SGLT2 inhibitors can improve cell life programming (22), arterial stiffness (23), cardiac structure and function (24, 25), and reduce cardiorenal effects and albuminuria (26, 27); hence, the strong cardiorenal efficacy observed in clinical trials (28).”
BackgroundRiemma, M. A., Mele, E., Donniacuo, M., Telesca, M., Bellocchio, G., Castaldo, G., Rossi, F., Angelis, A. D., Cappetta, D., Urbanek, K., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1422740 · Cited by 14
“SGLT2 inhibitors contribute to switching energy metabolism and reinstate mTOR activity in cardiovascular system, and by restoring mTOR cycle may interfere with a cognitive impairment (Packer, 2020; Stanciu et al., 2021).”
Endo, S., Kanamori, H., 吉田明弘, Naruse, G., Komura, S., Minatoguchi, S., Watanabe, T., Kawaguchi, T., Yamada, Y., Mikami, A., et al. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177355 · Cited by 15
Fang, Y. E., Paik, J. M., Ortega-Montiel, J., Tesfaye, H., Wexler, D. J., & Patorno, E. (2025) · Diabetes Care · doi:10.2337/dc25-1840 · Cited by 15
Starr, J. A., Pinner, N. A., Lisenby, K. M., & Osmonson, A. J. (2021) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2527 · Cited by 15
National Asthma Education and Prevention Program 2020 Guidelines: What’s Important for Primary Care
Murphy, M. (2021) · The Journal of Family Practice · doi:10.12788/jfp.0219 · Cited by 16
Mori, Y., Komura, T., Adomi, M., Yagi, R., Fukuma, S., Kondo, N., Yanagita, M., Duru, O. K., Tuttle, K. R., & Inoue, K. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02478-7 · Cited by 14
Hughes, C. B., Mussman, G. M., Ray, P., Bunn, R. C., Cornea, V., Thrailkill, K. M., Fowlkes, J. L., & Popescu, I. R. (2021) · Cell and Tissue Research · doi:10.1007/s00441-020-03358-8 · Cited by 12
Cardiovascular Outcome of the SGLT2 Inhibitor in Acute Myocardial Infarction: A Meta-Analysis
Hu, S., Tang, T., Yu, Q., Tong, X., You, Y., Zhang, S., Chen, C., Tang, J., Wang, C., Wang, H., et al. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm26136 · Cited by 10
“This in turn activates enzymes with antioxidant and anti-inflammatory properties, mainly silent mating type information regulation 2 homolog-1 (SIRT1) and adenosine 5’-monophosphate-activated protein kinase (AMPK), which improve heart function [33].”
Zhou, F., Xia, J., Liu, Y., He, W., Zhang, H., Keavney, B. D., Zi, M., Nguyen, B. Y., Mohamed, T., Miller, J. M., et al. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70094 · Cited by 10
“However, they also enhance autophagy by blocking nutrient-surplus sensors and activating AMPK while inhibiting mTOR signalling (Koyani et al., 2020; Lee et al., 2021; Li et al., 2021; Packer, 2020a, 2020b; Ren et al., 2021).”
SGLT2 inhibitors and autophagy in diabetes
Yaribeygi, H., Maleki, M., Atkin, S. L., Jamialahmadi, T., & Sahebkar, A. (2023) · Cell Biochemistry and Function · doi:10.1002/cbf.3792 · Cited by 12
“SGLT2 inhibition reduces the intracellular sodium and mimics nutrient (as well as oxygen) deprivation, which in turn could induce the autophagic cascade in cardiomyocytes.(57,63) This lysosome‐dependent process degrades damaged intracellular organelles, prevents cardiomyocyte dysfunction that results in improved myoca…”
BackgroundThe Off-Target Cardioprotective Mechanisms of Sodium–Glucose Cotransporter 2 Inhibitors: An Overview
Ionică, L. N., Furdui-Lința, A. V., Bătrîn, A. D., Hâncu, I. M., Lolescu, B. M., Dănilă, M. D., Petrescu, L., Mozos, I. M., Sturza, A., & Muntean, D. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147711 · Cited by 10
SGLT2 inhibitors: a new pillar of the heart failure regimen
DeSa, T. B., & Gong, T. (2021) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2204133 · Cited by 11
Botana, M., Escalada, J., Merchante, Á., Reyes‐García, R., & Rozas, P. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01277-1 · Cited by 11
“For example, glucosuria enhances gluconeogenesis and ketogenesis, probably by the activation of sirtuin-1, which induce a shift to a ‘‘fasting state’’ [45].”
BackgroundSung, P., Yue, Y., Chen, Y.-L., Chiang, J. Y., Cheng, B., Yang, C., Chai, H., & Yip, H. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117567 · Cited by 11
Cheema, H. A., Shafiee, A., Athar, M. M. T., Rafiei, M. A., Mehmannavaz, A., Jafarabady, K., Shahid, A., Ahmad, A. N., Ijaz, S. H., Dani, S. S., et al. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1273781 · Cited by 11
Autosis: a new form of cell death in myocardial ischemia–reperfusion injury
Yang, X., Wu, H. M., Zhou, G., Zhang, D., Yang, Q., Liu, Y., & Li, Y. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-04988-0 · Cited by 11
“NHE1 is predominantly expressed in cardiomyocytes, and its activity is markedly increased in pathological conditions such as diabetes mellitus, heart failure, and acute ischemia ‒ reperfusion injury[65].”
Sun, M., Wang, X., Lu, Z., Yang, Y., Lv, S., Miao, M., Chen, W., Wu, S., & Zhang, J. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101655 · Cited by 10
Haddad, F., Ataam, J. A., Amsallem, M., Cauwenberghs, N., Kuznetsova, T., Rosenberg‐Hasson, Y., Zamanian, R. T., Karakikes, I., Horne, B. D., Muhlestein, J. B., et al. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.12.012 · Cited by 8
Solomon, A. D., Dabral, S., Brajesh, R. G., Day, B. W., Juric, M., Zielonka, J., Bosnjak, Z. J., & Pant, T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26093966 · Cited by 13
“Large-scale clinical studies have shown substantial cardiovascular advantages, including a decreased risk of being hospitalized for heart failure or death from cardiovascular disease, even though these drugs were first created for their glycemic management qualities [271].”
Khayari, A. E., Hakam, S. M., Malka, G., Rochette, L., & Fatimy, R. E. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.101174 · Cited by 8
“22,52,53 Besides the whole-body metabolism shifts, other evidence suggests a fuel selection mechanism in the heart, where b -hydroxybutyrate is freely taken up by the heart and oxidized in preference to fatty acids, resulting in reduced myocardial oxygen demand, and improved mitochondrial function.”
BackgroundMetabolic effects of SGLT2i and metformin on 3-hydroxybutyric acid and lactate in db/db mice
Harada, M., Han, S., Shi, M., Ge, J., Yu, S., Adam, J., Adamski, J., Scheerer, M. F., Neschen, S., de Angelis, M. H., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.130962 · Cited by 9
Kawarasaki, S., Sawazaki, H., Iijima, H., Ng, S.-P., Kwon, J., Mohri, S., Iwase, M., Jheng, H., Takahashi, H., Nomura, W., et al. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s269916 · Cited by 7
Pan, D., Xu, L., Chen, P., Jiang, H., Shi, D., & Guo, M. H. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.683281 · Cited by 7
Primary Prevention of CVD with Aspirin: Benefits vs Risks
Weisman (2021) · The Journal of Family Practice · doi:10.12788/jfp.0222 · Cited by 9
Cardiac substrate utilization in heart failure: Where is the relevance of SGLT2 inhibition?
Mann, P. A., & Lehrke, M. (2021) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2021.02.092 · Cited by 8
Considerations and possibilities for sodium-glucose cotransporter 2 inhibitors in pediatric CKD
Kula, A. J. (2022) · Pediatric Nephrology · doi:10.1007/s00467-022-05456-x · Cited by 8
“It has been postulated that inhibition of SGLT2 on proximal tubule cells mimics a starvation state and generates protective effects through activation of the SIRT/AMPK pathway [59, 60].”
BackgroundRevisiting the full blood count: Circulating blood cells and their role in coagulation
Schofield, J., Yong, J., & Toh, C.-H. (2024) · British Journal of Haematology · doi:10.1111/bjh.19690 · Cited by 5
“102 The optimal management in these cases is unclear as an association with thrombosis was found in those who received therapeutic phlebotomy, but the thrombotic risk did not correlate with peak haematocrit levels.”
Sodium-glucose cotransporter type 2 inhibitors: successful running after two hares
Перепеч, Н. Б., & Mikhailova, I. E. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4534 · Cited by 13
SGLT2 Inhibitors: The Dawn of a New Era in Cardio-Metabolic Therapeutics
DEEDWANIA, P. C. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00495-5 · Cited by 6
Николаевна, К. О., Baranov, A. V., Sazhina, A. S., & Bogomolov, A. N. (2023) · Russian Journal of Preventive Medicine · doi:10.17116/profmed202326051102 · Cited by 6
Ovchinnikov, A. G., Borisov, A. A., Zherebchikova, K., Рябцева, О. Ю., Gvozdeva, A. D., Masenko, V. P., Ageev, F. T., & Boytsov, S. A. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4304 · Cited by 11
Piccirillo, F., Lanciotti, M., Nusca, A., Frau, L., Spanò, A., Liporace, P., Ussia, G. P., & Grigioni, F. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052103 · Cited by 6
“↑ ketone production and enhanced ATP synthesis with reduced oxygen consumption [141–143] ↑ mitochondrial efficiency in ischemic myocardium [144] Ion Homeostasis in Ischemia ↓ intracellular sodium and calcium, preventing ion overload and cell damage.”
Song, K., Liang, D., Xiao, D., Kang, A., & Ren, Y. (2024) · Molecular Medicine Reports · doi:10.3892/mmr.2024.13323 · Cited by 6
“However, obesity in turn inhibits autophagy activation (80), and the effect of reduced fat load on autophagy after bariatric surgery should not be ignored.”
BackgroundGliflozinas: más que antidiabéticos orales. Una breve revisión de la literatura
González, V. (2021) · Revista Uruguaya de Cardiología · doi:10.29277/cardio.36.2.8 · Cited by 11
Johri, N., Matreja, P. S., John, D., Dutta, S., Parida, A. K., & Sarma, S. N. (2022) · Current Molecular Pharmacology · doi:10.2174/1874467216666221017123333 · Cited by 5
Ndiaye, J. F., Nekka, F., & Craig, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15031002 · Cited by 8
“These benefits suggested that SGLT2 inhibitors could add cardioprotective and renoprotective effects in patients with established heart failure, including those with and without diabetes [62,63].”
BackgroundJames, N., Gerrish, L., Rokotyan, N., & Gladding, P. A. (2021) · medRxiv · doi:10.1101/2021.07.26.21261115 · Cited by 5
“These effects seem to operate at the level of aging related pathways such as SIRT1 and AMPK (38, 39) possibly indicating a role beyond heart failure and diabetes.”
BackgroundEmpagliflozin to Prevent Doxorubicin Cardiotoxicity
Guo, Z., & Javaheri, A. (2025) · JACC CardioOncology · doi:10.1016/j.jaccao.2025.01.005 · Cited by 5
Hushmandi, K., Salarizadeh, N., Einollahi, B., Izadi, M., Doosti, P., Behzadnia, M. J., Cho, W. C., Yousefi, T., Khoshnazar, S. M., Alimohammadi, M., et al. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01824-0 · Cited by 4
“Furthermore, Packer has shown that SGLT2 inhibitors, through the activation of the SIRT1/AMPK signal - ing axis, mitigate the progression of cardiomyopathy by reducing inflammation, enhancing mitochondrial function, inhibiting reactive oxygen species (ROS), and alleviating microvascular injury [72].”
Sodium-glucose Cotransporter 2 Inhibitors and Pathological Myocardial Hypertrophy
Gao, Z., Bao, J., Hu, Y., Tu, J., Ye, L., & Wang, L. (2023) · Current Drug Targets · doi:10.2174/1389450124666230907115831 · Cited by 5
Treatment of acromegaly-induced diabetes: an updated proposal
Biagetti, B., Castro, M. A., Marazuela, M., & Puig‐Domingo, M. (2024) · Pituitary · doi:10.1007/s11102-024-01477-x · Cited by 5
“SGLT2i have demonstrated to restore the mTOR pathway activity by re-synchronizing disrupted cellular signaling to its physiologic rhythmic pattern as well as improving cellular autophagy and metabolic stress management [ 75, 76].”
Bauer, K. I., Baker, D., Lerner, R., Koeck, T., Buch, G., Fischer, Z., Martens, R., Esenkova, E. E., Nuber, M., Andrade-Navarro, M. A., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02916-0 · Cited by 8
Carrera‐Bastos, P., Muskiet, M. H. A., Ordóñez, F. M., Pruimboom, L., Lucía, A., Luque, R. M., & Muskiet, F. A. J. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09996-z · Cited by 8
Ramos-Román, M. A. (2025) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2024.0182 · Cited by 4
Obesity 2021: Current Clinical Management of a Chronic, Serious Disease
Kushner (2021) · The Journal of Family Practice · doi:10.12788/jfp.0221 · Cited by 8
Inhibition of sodium-glucose cotransporter 2 to slow the progression of chronic kidney disease
Oguz, F., Demoulin, N., Thissen, J. P., Jadoul, M. Y., & Morelle, J. (2021) · Acta Clinica Belgica · doi:10.1080/17843286.2021.1966583 · Cited by 5
Park, S., Jeong, H. E., Bea, S., Yu, O. H. Y., Cho, Y. M., You, S. C., Man, K. K. C., & Shin, J. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15221 · Cited by 5
Emerging Pharmacologic Therapies for Heart Failure With Reduced Ejection Fraction
Chaudhary, A., Alreefi, F., & Aziz, M. (2021) · CJC Open · doi:10.1016/j.cjco.2021.01.006 · Cited by 4
“Another recent theory relates to a starvation stress response, which is blunted in diabetic patients with HF, because diabetes is a state of energy oversupply and SGLT2 inhibitors mimic a state of energy deprivation and therefore activate this protective transcription program.(31,36) Regardless of the underlying mecha…”
BackgroundScreening for Autoantibodies in Type 1 Diabetes: A Call to Action
Петерс (2021) · The Journal of Family Practice · doi:10.12788/jfp.0223 · Cited by 11
Emerging roles of Sodium-glucose cotransporter 2 inhibitors in Diabetic kidney disease
Gan, T., Song, Y., Guo, F., & Qin, G. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07758-7 · Cited by 4
SGLT2 inhibitors for kidney protection in children: expanding horizons beyond endocrinology
Pucci, C., Marazza, D. S., Preka, E., Mastrangelo, A., Montini, G., & Boyer, O. (2025) · Pediatric Nephrology · doi:10.1007/s00467-025-06838-7 · Cited by 9
Erythrocytosis and thromboembolic risks associated with SGLT2 inhibitors in type 2 diabetes
Chen, Y., Hsieh, T. Y. J., Sun, A. Y.-E., Chen, K., Choi, E., Rastogi, N., Cheng, J., Wei, J. C.-C., & Lee, C. (2025) · Scientific Reports · doi:10.1038/s41598-025-31726-3 · Cited by 5
“These advancements could pave the way for personalized therapy and improve patient outcomes 23,24 .”
Alrasheed, R., Altaf, A. F., Althurwi, A. H., Alrodan, S. F., Asiri, M. H., Alsaluli, B. A., Alsurur, M., Alghamdi, K. A., Alrowaithi, A. A., & Almalki, N. S. (2025) · Medicina · doi:10.3390/medicina62010069 · Cited by 6
“…drugs function by encouraging the elimination of sodium through urine, enhancing circulation, decreasing the heart’s preload and afterload, lowering blood pressure, supporting moderate weight loss, improving heart muscle metabolism, and possibly mitigating oxidative stress and inflammation [11,12].”
Lee, C., Fang, T., Jen, C.-H., Huang, H.-C., & Chuang, Y. (2026) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2026.05.067 · Cited by 5
AMPK Signalling in Heart Failure: From Metabolic Sensor to Context-Dependent Therapeutic Target
Arzouni, R., Aazar, R. F. M., Asakrieh, S., Cattan, S., & Jovanović, A. (2026) · Biomedicines · doi:10.3390/biomedicines14061362 · Cited by 5
“Large randomized trials have demonstrated consistent reductions in heart failure hospitalization and composite cardiovascular outcomes [47,51].”
InfluentialIntermittent fasting to treat diabetes: time to update clinical practice guidelines
Varady, K. A., Chow, L. S., & Peterson, C. M. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00119-1 · Cited by 4
Zaini, L. M., Kartasasmita, A., Gondhowiardjo, T. D., Syukri, M., & Lesmana, R. (2022) · Expert Review of Ophthalmology · doi:10.1080/17469899.2022.2111302 · Cited by 3
“T2DM is perceived as a state of energy overabundance, thus suppressing SIRT1/AMPK and autophagy [60].”
BackgroundTommerdahl, K. L., Kula, A. J., & Bjornstad, P. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2203319 · Cited by 6
Liao, Y.-J., Chen, C., Lin, H.-T., Pei, D., & Liang, Y.-J. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2467658 · Cited by 3
“Empagliflozin Lowering insulin levels through regulating Akt/mTOR and SIRT1/AMPK, two cellular energy sensors [60].”
Heart Failure and Diabetes: Perspective of a Dangerous Association
Favaloro, L. E., Ratto, R., & Musso, C. (2021) · Current Hypertension Reviews · doi:10.2174/1573402117666210406111927 · Cited by 4
Барбараш, О. Л., Анатольевна, Г. А., Гоголашвили, Н. Г., Efremushkina, A. A., Леонидович, Ж. С., Кашталап, В. В., Korennova, O. Y., Макаров, С. А., Афанасьевна, Н. В., Протасов, К. В., et al. (2021) · Complex Issues of Cardiovascular Diseases · doi:10.17802/2306-1278-2021-10-1-103-108 · Cited by 3
SGLT2 inhibitors in patients with HFpEF: how old is too old?
Tong, D. (2022) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2022.30 · Cited by 3
Diallo, A., Villard, O., Carlos‐Bolumbu, M., Renard, É., & Galtier, F. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15335 · Cited by 4
Sodium-Glucose Cotransporter-2 Inhibitors and Uric Acid
Sánchez‐Lozada, L. G., Lanaspa, M. A., Rodríguez‐Iturbe, B., Brown, J. M., Madero, M., & Johnson, R. J. (2025) · The Nephron journals/Nephron journals · doi:10.1159/000545131 · Cited by 3
“Packer has suggested that physiology is similar to switching into starvation mode despite nutrient surplus [5 – 7] (Fig.”
Application of SGLT2 inhibitors in kidney diseases: a bibliometric analysis
Hu, Q., Jin, H., Li, X., & Hu, L. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1768225 · Cited by 3
Park, S. J., Kim, H. J., Seo, M., Byun, D. W., Suh, K., Yoo, M. H., Yang, H., Lee, I., Kwon, S. H., Kim, M., et al. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-105271 · Cited by 5
Physiology of Kidney Glucose Transport and Mechanisms of Kidney Protection by SGLT2 Inhibitors
Vallon, V. (2026) · Handbook of experimental pharmacology · doi:10.1007/164_2026_828 · Cited by 4
Schoenborn, E. M., Skersick, P., THRASHER, C., & nd, R. L. P. (2023) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2839 · Cited by 2
Kakzanov, Y., Sevilya, Z., Goldman, A., Cipok, M., Hershkovitz, V., Bryk, G., & Lev, E. I. (2024) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001581 · Cited by 2
Update on Sodium Glucose Cotransporter Type 2 Inhibitors Use in Kidney Transplant Patients
Salvadori, M., Rosati, A., & Rosso, G. (2024) · Transplantology · doi:10.3390/transplantology5030022 · Cited by 2
“[10–14].”
Pagel, P. S., Hang, D., Freed, J. K., & Crystal, G. J. (2025) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2025.06.015 · Cited by 4
Ashraf, H., Karbalai, S., & Jamali, R. (2021) · World Journal of Meta-Analysis · doi:10.13105/wjma.v9.i2.164 · Cited by 2
Athiyaman, S., Randhi, B., Gutlapalli, S. D., Pu, J., Zaidi, M. F., Patel, M., Atluri, L. M., Gonzalez, N. A., Sakhamuri, N., & Venugopal, S. (2022) · Cureus · doi:10.7759/cureus.29896 · Cited by 2
“These advantages for the heart and kidneys are unique to SGLT2 inhibitors [21].”
BackgroundYahr, J., Calle, J., & Taliercio, J. J. (2021) · Journal of Osteopathic Medicine · doi:10.1515/jom-2021-0150 · Cited by 5
Shen, X., & Shen, X. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14005 · Cited by 2
“ment of cardiomyopathy; all these effects promote homoeostasis and survival.(74) Some of these consequences of the adaptive cellular changes have been supported by experimental data from animal models.”
BackgroundKhan, M. S., Fonarow, G. C., & Greene, S. J. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2170 · Cited by 2
Mochel, J. P., Ward, J. L., Blondel, T., Kundu, D., Merodio, M. M., Zemirline, C., Guillot, E., Giebelhaus, R. T., de la Mata, A. P., Iennarella‐Servantez, C. A., et al. (2023) · Research Square · doi:10.22541/au.170022092.29999283/v1 · Cited by 2
Kelemen, H., Mărcuțiu, P.-E., & Adrienn, R. (2023) · Orvostudományi Értesítö · doi:10.2478/orvtudert-2023-0009 · Cited by 1
Yen, F., Wei, J. C., Hung, Y., Liu, J., Hwu, C., & Hsu, C. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113267 · Cited by 1
Zediker, M., Franklin, J., Davis, K., & Yunusa, I. U. (2026) · International Journal of Clinical Practice · doi:10.1155/ijcp/5197466 · Cited by 2
Nitric oxide redox signaling as a convergent mechanism in aging and fibrosis
Guo, X., Cao, Y., Liu, L., Peng, Y., Du, Y., Yang, F., & Huang, D. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103156 · Cited by 1
Jiang, Y., Jia, S., tian, D., Qiang, H., Zhao, H., Chen, X., Su, X., & Jia, X. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-026-07904-4 · Cited by 2
New Perspectives in COPD Management
Yawn (2021) · The Journal of Family Practice · doi:10.12788/jfp.0220 · Cited by 2
Барбараш, О. Л., Кашталап, В. В., Анатольевна, Г. А., Протасов, К. В., Korennova, O. Y., Гоголашвили, Н. Г., Salasyuk, A. S., Efremushkina, A. A., Леонидович, Ж. С., Зенин, С. А., et al. (2021) · Complex Issues of Cardiovascular Diseases · doi:10.17802/2306-1278-2021-10-3-121-129 · Cited by 1
The use of dapaglifl ozin in a comorbid patient: new perspectives
Паневин, Т. С., Елисеев, М. С., Bobkova, A. O., Dimitreva, A. E., & Urumova, M. M. (2023) · Nephrology (Saint-Petersburg) · doi:10.36485/1561-6274-2023-27-2-109-115 · Cited by 2
Khwaldeh, A., Al‐Sawalha, N. A., Aljabali, S. M., Shraideh, Z. A., Ababneh, S., & Bdeir, R. (2023) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/2787 · Cited by 1
Neuroprotective potential of gliflozins
Kokin, A. S., & Суплотова, Л. А. (2023) · Diabetes Mellitus · doi:10.14341/dm13085 · Cited by 3
Understanding Heart Failure: Evolution of Concepts and Treatments
Šmalcelj, A. (2024) · Cardiologia Croatica · doi:10.15836/ccar2024.251 · Cited by 1
“This is due to SGLT2i-induced decline in hepcidin and ferritin levels. which alleviates functional iron deficit mediated by the HF inflammatory milieu 156,162,163 .”
Mani, S., Balasubramanian, A., Veluswami, K., Rao, S., & Aggarwal, S. (2024) · Cureus · doi:10.7759/cureus.63796 · Cited by 4
“This, in succession, activates the enzymes possessing antioxidant and anti-inflammatory properties, mainly SIRT1 and AMPK, which improve cardiac function [36,37].”
BackgroundContemporary prospects for the use of sodium-glucose cotransporter-2 inhibitors
Kondratieva, A. R., Khazova, E. A., Lobanova, A. V., Sorokina, Y. А., Mosinа, A. A., & Занозина, О. В. (2024) · Perm Medical Journal · doi:10.17816/pmj41692-108 · Cited by 1
EMPEROR-Reduced trial: empagliflozin in patients with heart failure and low ejection fraction
Špinar, J., Špinarová, L., & Vítovec, J. (2020) · Intervenční a akutní kardiologie · doi:10.36290/kar.2020.051 · Cited by 1
Resolution of the online meeting of Russian experts on the EMPEROR-REDUCED trial
Arutyunov, G. P., Arutyunov, A. G., Tarlovskaya, E. I., As, A., Георгиевна, В. Н., Анатольевна, Г. А., Глезер, М. Г., Жиров, И. В., Ilyin, M. V., Koziolova, N. A., et al. (2020) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2020-4167 · Cited by 1
Self-citationEfficacy of sodium-glucose co-transporter-2 inhibitors in patients with heart failure
Kovalenko, E. V., Витальевна, Л. М., Arabidze, G. G., & Kryakushkin, V. G. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4235 · Cited by 2
Batyushin, М. М., Вачугова, А. А., Gilyarevskiy, S. R., Dzherieva, I. S., Zakaryaeva, N. A., Zykov, M. V., Ivanenko, V. V., Isaeva, U. S., Кanorskiy, S. G., Kiselevа, M. A., et al. (2021) · South Russian Journal of Therapeutic Practice · doi:10.21886/2712-8156-2021-2-2-104-110 · Cited by 1
Metadata
- Authors
- Packer, M.
- Affiliations
- Baylor University Medical Center (US)
- Corresponding author
- Packer, Milton
- ORCID
- Packer, Milton
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-02-11
- Volume
- 43
- Issue
- 3
- Pages
- 508-511
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W3008610985
- Semantic Scholar
- 18ef104bcf8e540a8930b852692198f550512f79
- Cited by
- 247
- References
- 52
- Citations by year
- 2026: 24 · 2025: 31 · 2024: 29 · 2023: 37 · 2022: 33 · 2021: 71 · 2020: 22
- FWCI
- 30.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- SGLT2 inhibitors, cardiorenal benefits, cellular reprogramming, ketogenesis, ketone bodies, heart failure hospitalization, end-stage renal disease, type 2 diabetes, energy metabolism
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Fasting, Humans, Hypoglycemic Agents, Sodium-Glucose Transporter 2, Cellular Reprogramming
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.